The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland, Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2023 Results Conference Call November 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants Yuko Oku - Morgan Stanley Kyle Boucher - TD Cowen Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter ...

[Unaudited Interim Condensed Consolidated Financial Statements](index=2&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) [Unaudited Interim Condensed Consolidated Statements of Loss](index=3&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Loss) Revenue grew **32.6%** to **$45.3 million**, with net loss decreasing **25.3%** to **$54.9 million** Consolidated Statement of Loss Highlights (in USD thousands) | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | YoY Change | | :--- | :--- | :--- | :--- | | **Revenue** | $45,323 | $34,176 | +32.6% | | **Gross Profit** | $31,014 | $21,624 | +43.4% | | **Operating Loss** | $(55,879) | $(72,739) | -23.2% | | **Loss for the period** | $(54,920) | $(73,478) | -25.3% | | **Basic and diluted loss per share** | $(0.85) | $(1.15) | -26.1% | [Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss](index=4&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) Total comprehensive loss improved to **$52.9 million**, driven by reduced net loss and positive currency translation Consolidated Statement of Comprehensive Loss (in USD thousands) | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Loss for the period | $(54,920) | $(73,478) | | Currency translation differences | $2,269 | $(10,249) | | **Total comprehensive loss for the period** | **$(52,934)** | **$(81,274)** | [Unaudited Interim Condensed Consolidated Balance Sheets](index=5&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$205.9 million** due to reduced cash, with liabilities rising and equity falling to **$158.4 million** Key Balance Sheet Items (in USD thousands) | Asset/Liability/Equity | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $132,767 | $161,305 | | Total assets | $205,852 | $243,838 | | Total liabilities | $47,413 | $43,708 | | Total equity | $158,439 | $200,130 | [Unaudited Interim Condensed Consolidated Statements of Changes in Equity](index=6&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Equity) Total equity decreased from **$200.1 million** to **$158.4 million**, primarily due to a **$54.9 million** net loss Equity Reconciliation for Nine Months Ended Sep 30, 2023 (in USD thousands) | Description | Amount | | :--- | :--- | | Equity as of January 1, 2023 | $200,130 | | Loss for the period | $(54,920) | | Other comprehensive income | $1,986 | | Share-based compensation | $11,036 | | Other transactions with owners | $207 | | **Equity as of September 30, 2023** | **$158,439** | [Unaudited Interim Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$37.3 million**, with cash decreasing to **$132.8 million** Net Cash Flow Summary (in USD thousands) | Cash Flow Activity | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Net cash flows used in operating activities | $(37,283) | $(59,764) | | Net cash flow provided from investing activities | $10,569 | $29,835 | | Net cash flow used in financing activities | $(2,311) | $(988) | | **Cash and cash equivalents at end of the period** | **$132,767** | **$157,827** | [Notes to the Unaudited Interim Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) Detailed disclosures cover company background, accounting policies, revenue, balance sheet, and income statement items [Note 1: Company Information](index=9&type=section&id=1.%20Company%20information) SOPHiA GENETICS SA, a Swiss cloud-native software company, reduced D&O insurance cash from **$30 million** to **$15 million** - The company is a cloud-native software company in the healthcare space, commercializing its SOPHiA DDM™ platform for analyzing complex multimodal datasets[17](index=17&type=chunk) - In June **2023**, the company reduced the designated cash set aside for its Directors and Officers Insurance Policy from **$30 million** to **$15 million**[24](index=24&type=chunk) - As of September **30**, **2023**, the company held **11,766,158** treasury shares, a significant increase from **2,257,163** held a year prior, primarily for administering equity incentive programs[33](index=33&type=chunk) [Note 2: Fair Value](index=11&type=section&id=2.%20Fair%20Value) Financial assets and liabilities' carrying amounts approximate fair values as of September **30**, **2023**, with no significant changes - The carrying amount of financial assets and liabilities, including cash, accounts receivable, and accounts payable, is a reasonable approximation of their fair value as of September **30**, **2023**[35](index=35&type=chunk) [Note 3: Financial Risk Management](index=12&type=section&id=3.%20Financial%20Risk%20Management) The company faces credit, liquidity, and market risks, with no significant changes in risk management since year-end **2022** - The company is exposed to credit, funding, liquidity, and market risks, with no significant changes in its risk management approach since December **31**, **2022**[36](index=36&type=chunk) [Note 4: Segment Reporting](index=12&type=section&id=4.%20Segment%20Reporting) The company operates as a single segment, with the CEO reviewing financial information on a consolidated basis - The company operates in a single operating segment, and its performance is assessed as a whole by the senior management team led by the CEO[37](index=37&type=chunk) [Note 5: Revenue](index=12&type=section&id=5.%20Revenue) Revenue primarily from SOPHiA DDM™ Platform, with EMEA contributing **71%** and NORAM **16%**, both showing strong growth Revenue by Geographic Region (in USD thousands) | Region | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | YoY Growth | | :--- | :--- | :--- | :--- | | EMEA | $32,378 | $25,288 | +28.0% | | NORAM | $7,268 | $4,656 | +56.1% | | LATAM | $3,062 | $2,189 | +39.9% | | APAC | $2,615 | $2,043 | +28.0% | | **Total** | **$45,323** | **$34,176** | **+32.6%** | Revenue by Stream (in USD thousands) | Revenue Stream | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | SOPHiA DDM Platform | $44,331 | $32,884 | | Workflow equipment and services | $992 | $1,292 | [Note 6: Accounts Receivable](index=13&type=section&id=6.%20Accounts%20receivable) Net accounts receivable increased to **$9.8 million** from **$6.6 million**, driven by a rise in accrued contract revenue Accounts Receivable Breakdown (in USD thousands) | Component | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Accounts receivable | $4,631 | $6,060 | | Accrued contract revenue | $6,064 | $1,499 | | Allowance for expected credit losses | $(1,056) | $(1,095) | | **Net accounts receivable** | **$9,781** | **$6,649** | [Note 7: Loss Per Share](index=13&type=section&id=7.%20Loss%20per%20share) Loss per share improved to **$0.85** from **$1.15** for the nine months ended September **30**, **2023**, on **64.6 million** shares Loss Per Share Calculation | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Net loss attributed to shareholders (USD thousands) | $(54,920) | $(73,478) | | Weighted average number of shares in issue | 64,607,758 | 64,058,859 | | **Basic and diluted loss per share** | **$(0.85)** | **$(1.15)** | [Note 8: Leases](index=14&type=section&id=8.%20Leases) In June **2023**, a **108**-month lease for new R&D office space in France recorded a **$2.3 million** right-of-use asset and liability - On June **1**, **2023**, the company entered into a **108**-month lease for office space in Bidart, France, to support R&D expansion, recording a right-of-use asset and lease liability of **$2.3 million**[43](index=43&type=chunk) [Note 9: Borrowings](index=14&type=section&id=9.%20Borrowings) A revolving credit facility of up to **CHF 5.0 million** with Credit Suisse had no outstanding borrowings as of September **30**, **2023** - The company has a credit facility of up to **CHF 5.0 million** with Credit Suisse, with no borrowings outstanding as of September **30**, **2023**[44](index=44&type=chunk) [Note 10: Share-based Compensation](index=14&type=section&id=10.%20Share-based%20compensation) Share-based compensation expense totaled **$11.04 million**, consistent with prior year, largely from general and administrative functions Share-based Compensation Expense (in USD thousands) | Department | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Research and development | $2,489 | $1,732 | | Sales and marketing | $794 | $1,175 | | General and administrative | $7,753 | $8,110 | | **Total** | **$11,036** | **$11,017** | [Note 11: Related Party Transactions](index=14&type=section&id=11.%20Related%20party%20transactions) Key management compensation increased to **$11.0 million** from **$9.1 million**, driven by higher salaries and share-based compensation Key Management Compensation (in USD thousands) | Compensation Type | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Salaries and other short-term benefits | $2,814 | $1,613 | | Share-based compensation expense | $7,713 | $7,061 | | **Total** | **$10,994** | **$9,109** | [Note 12: Events After the Reporting Date](index=15&type=section&id=12.%20Events%20after%20the%20reporting%20date) No material subsequent events requiring recognition or disclosure were identified after the reporting date through November **7**, **2023** - There were no material events after the reporting date that required recognition or disclosure in the financial statements[49](index=49&type=chunk)

SOPHiA GENETICS SA (NASDAQ:SOPH) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Katherine Bailon - Head, Investor Relations Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - Chief Financial Officer and COO Conference Call Participants Edmund Tu - Morgan Stanley Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Vidyun Bais - BTIG Operator Hello, ladies and gentlemen. And thank you for joining SOPHiA GENETICS Second Quarter 2020 Earnings Call. Our host for today is Katherin ...

Table of Contents | | Unaudited Interim Condensed Consolidated Financial Statements | F-2 | | --- | --- | --- | | – | Unaudited Interim Condensed Consolidated Statements of Loss | F-3 | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss | F-4 | | – | Unaudited Interim Condensed Consolidated Balance Sheets | F-5 | | – | Unaudited Interim Condensed Consolidated Statements of Changes in Equity | F-6 | | – | Unaudited Interim Condensed Consolidated Statements of Cash Flows | F-8 | | ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President of Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - Chief Financial Officer and Chief Operating Officer Conference Call Participants Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase & Co. Kyle Boucher - TD Cowen Operator Good morning, and welcome to the SOPHiA GENETICS' First Quarter 2023 Earnings Conference Call ...

Revenue and Profitability - Revenue for Q1 2023 was $13,966 thousand, a 28.9% increase from $10,861 thousand in Q1 2022[5] - Gross profit for the period was $9,694 thousand, compared to $6,710 thousand in the same period last year, reflecting a 44.5% increase[5] - Revenue from the SOPHiA DDM Platform was $13.749 million, up from $10.431 million, indicating a growth of 31.5% year-over-year[36] - Total revenue for the three months ended March 31, 2023, was $13.966 million, representing a 28.9% increase from $10.861 million in the same period of 2022[35] Loss and Financial Performance - Operating loss decreased to $19,287 thousand in Q1 2023 from $25,021 thousand in Q1 2022, representing a 22.0% improvement[5] - Loss for the period was $19,700 thousand, down from $25,487 thousand in Q1 2022, indicating a 22.8% reduction[7] - The net loss attributed to shareholders for the three months ended March 31, 2023, was $19.700 million, an improvement from a net loss of $25.487 million in the same period of 2022[41] - Total comprehensive loss for Q1 2023 was $17,799 thousand, compared to $27,020 thousand in Q1 2022, a decrease of 34.2%[7] Cash Flow and Assets - Cash and cash equivalents at the end of Q1 2023 were $160,762 thousand, slightly down from $161,305 thousand at the end of 2022[10] - Total assets decreased to $232,058 thousand as of March 31, 2023, from $243,838 thousand at the end of 2022[10] - Accounts receivable increased to $7.696 million as of March 31, 2023, compared to $6.060 million as of December 31, 2022, reflecting a 26.9% rise[40] - The Company had no borrowings outstanding under its credit facility as of March 31, 2023[43] Shareholder Information - The company reported a basic and diluted loss per share of $0.31 for Q1 2023, an improvement from $0.40 in Q1 2022[5] - The weighted average number of shares in issue increased to 64,242,871 as of March 31, 2023, compared to 63,891,630 in the prior year[41] - The Company held 2,072,700 treasury shares as of March 31, 2023, down from 2,483,000 shares held as of March 31, 2022[30] Compensation and Expenses - Share-based compensation expense totaled $2.430 million for the three months ended March 31, 2023, compared to $3.471 million in the same period of 2022, indicating a decrease of 30%[44] - Total compensation for key management and non-executive directors decreased to $2,439,000 in Q1 2023 from $2,520,000 in Q1 2022, a decline of approximately 3.2%[47] - Share-based compensation expense reduced to $1,720,000 in Q1 2023 from $1,900,000 in Q1 2022, representing a decrease of about 9.5%[47] - Salaries and other short-term employee benefits slightly decreased to $551,000 in Q1 2023 compared to $553,000 in Q1 2022, a decline of approximately 0.4%[47] - Pension costs increased to $52,000 in Q1 2023 from $50,000 in Q1 2022, reflecting a growth of 4%[47] - Other compensation rose significantly to $116,000 in Q1 2023 from $17,000 in Q1 2022, marking an increase of approximately 582.4%[47] Other Information - The Company operates in a single operating segment, with financial performance assessed as such by senior management[34] - There were no material subsequent events reported after the reporting date[48]

SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2022 Results Earnings Conference Call March 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President, Investor Relations Jurgi Camblong - Founder and Chief Executive Officer Ross Muken - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Richard Hilliker, Jr. - Credit Suisse Mark Massaro - BTIG Marta Nazarovets - J.P. Morgan Operator Good morning and welcome to SOPHiA GENETICS' Fourth Quarter Fisca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (For the fiscal year ended December 31, 2022) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland +41 21 694 10 60 (Address of principal executive offices) Ross Muken OR o TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2022 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the consolidated financial statements 2022 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the consolidated financial statements Opinion We have audited the consolidated financial statements of SOPHiA GENETICS SA and its subsidiaries (the Group), which comprise ...